We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lipomics to Partner with University of California for Personalized Medicine Research

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Lipomics Technologies, Inc., a privately held company that specializes in the analysis of lipid metabolites, has announced that it has entered into an agreement with the University of California, Davis to collaborate on research projects with an emphasis on personalized medicine.
Lipomics will retain certain rights to develop diagnostic applications based on the data from the studies. Lipomics seeks to partner with academic institutions and drug companies to advance its goal of developing diagnostic tests for metabolic diseases.
“This is a valuable collaboration as we pursue discovery of markers for health and disease. Understanding individual response is essential to understanding metabolic disease and approaches to therapy and preventative care. We look forward to working with one of the nation’s premier research institutions,” said Steve Watkins, president and chief scientific officer at Lipomics.